amifostine anhydrous has been researched along with pentoxifylline in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Andrews, C; Andric, T; Dar, S; Gezer, S; Gregory, S; Hsu, WT; Huang, RW; Lisak, L; Loew, J; Qawi, H; Raza, A; Rifkin, S; Robin, E; Venugopal, P | 1 |
| Damron, TA; Farnum, CE; Horton, JA; Margulies, BS; Spadaro, JA; Strauss, JA | 1 |
| Damron, TA; Farnum, CE; Horton, JA; Luther, J; Margulies, BS; Spadaro, JA; Strauss, JA | 1 |
| Bilgi, O; Erikci, AA; Kandemir, EG; Karagoz, B; Ozturk, A; Top, C; Turken, O | 1 |
1 review(s) available for amifostine anhydrous and pentoxifylline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 other study(ies) available for amifostine anhydrous and pentoxifylline
| Article | Year |
|---|---|
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Patients with myelodysplastic syndromes benefit from palliative therapy with amifostine, pentoxifylline, and ciprofloxacin with or without dexamethasone.
Topics: Adult; Aged; Aged, 80 and over; Amifostine; Anorexia; Antineoplastic Combined Chemotherapy Protocols; Blood Cell Count; Ciprofloxacin; Dexamethasone; Female; Gastrointestinal Diseases; Hematologic Diseases; Humans; Hypotension; Male; Middle Aged; Myelodysplastic Syndromes; Palliative Care; Pentoxifylline; Treatment Outcome | 2000 |
Combinations of radioprotectants spare radiation-induced damage to the physis.
Topics: Amifostine; Animals; Body Weight; Bone Density; Bone Development; Drug Therapy, Combination; Femur; Growth Plate; Leg Length Inequality; Male; Misoprostol; Pentoxifylline; Radiation Dosage; Radiation Injuries, Experimental; Radiation-Protective Agents; Rats; Rats, Sprague-Dawley; Selenium; Tibia | 2004 |
Radioprotectant combinations spare radiation-induced damage to the physis more than fractionation alone.
Topics: Amifostine; Animals; Anti-Ulcer Agents; Bone Development; Disease Models, Animal; Dose Fractionation, Radiation; Knee Joint; Male; Misoprostol; Pentoxifylline; Radiation Injuries; Radiation-Protective Agents; Random Allocation; Rats; Rats, Sprague-Dawley; Tibia | 2005 |
Results of combination therapy with amifostine, pentoxifylline, ciprofloxacin and dexamethasone in patients with myelodysplastic syndrome and acute myeloid leukemia.
Topics: Adult; Aged; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Ciprofloxacin; Dexamethasone; Female; Hematopoiesis; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Pancytopenia; Pentoxifylline; Retrospective Studies; Treatment Outcome | 2008 |